Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06164951 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia
A Phase 3 study, sponsored by QED Therapeutics, a BridgeBio company.
- Completed
- Registry status
- Phase 3
- Development phase
- 114
- Enrollment target
NCT06164951: Completed Phase 3 study, sponsored by QED Therapeutics, a BridgeBio company.
NCT06164951 is a Phase 3 study that has completed, run by QED Therapeutics, a BridgeBio company. The registered enrollment target is 114 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06164951, a Phase 3 study, has completed, sponsored by QED Therapeutics, a BridgeBio company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 114 participants
- Enrollment target
Study Summary
This is a Phase 3, multicenter, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of infigratinib in children and adolescents with achondroplasia (ACH) who have completed at least 26 weeks of participation in the QED-sponsored study PROPEL (QBGJ398-001).
Interventions
- DRUG Infigratinib 0.25 mg/kg/day
- DRUG Placebo Comparator 0.25 mg/kg/day
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2023-11-10 |
| Est. Completion | 2025-12-18 |
| Phase | Phase 3 |
What the finished NCT06164951 record still lists
NCT06164951 is an interventional study that assigns participants to a tested intervention. The registered 114 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 2 interventions - of which Infigratinib 0.25 mg/kg/day is the first listed.
NCT06164951 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06164951 about?
NCT06164951 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia". This is a Phase 3, multicenter, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of infigratinib in children and adolescents with achondroplasia (ACH) who have completed at least 26 weeks of participation in the QED-sponsored study PROPEL (QBGJ398-001).
What is the current status of trial NCT06164951?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 114 participants. The study started on 2023-11-10. Estimated completion is 2025-12-18.
What interventions are being tested in trial NCT06164951?
The interventions under investigation include: Infigratinib 0.25 mg/kg/day (DRUG), Placebo Comparator 0.25 mg/kg/day (DRUG).
Who is sponsoring clinical trial NCT06164951?
This trial is sponsored by QED Therapeutics, a BridgeBio company, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06164951's enrollment target sits among peer trials
114 1648th of 2000 higher than 350 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04522791 · 114 participants · Phase 2
Breathing, Relaxation, Attention Training, & Health in Older Adults (BREATHE)
- NCT04875052 · 114 participants · NA
Vibration and Post-traumatic Osteoarthritis Risk Following ACL Injury
- NCT05100342 · 114 participants
Prospective Validation of a Points Score System Predicting 30-day Survival
- NCT05224089 · 114 participants · Phase 4
Bilateral TAP and RS Blocks Using Liposomal Bupivacaine/Bupivacaine vs. Regular Bupivacaine in Laparoscopic Colectomy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI